🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07569874
Starting soon Not applicable

Thulium Laser Enucleation With Bladder Neck Incision for Small-Volume Benign Prostatic Hyperplasia

NCT07569874 · tracked via the Priya Life Science China tracker
Sponsor
Chinese PLA General Hospital
Phase
Not applicable
Started
2026-07
Last updated
2026-07-21

Condition(s) studied

Benign Prostatic HyperplasiaBladder Outlet ObstructionLower Urinary Tract Symptoms (LUTS)

Investigational drug(s) / intervention(s)

Thulium Laser Enucleation of the Prostate Combined With Bladder Neck IncisionThulium Laser Enucleation of the ProstateTransurethral Resection of the ProstateTransurethral Incision of the Prostate

Thulium Laser Enucleation of the Prostate Combined With Bladder Neck Incision: Participants will undergo transurethral thulium laser enucleation of the prostate combined with bladder neck incision. Hyperplastic prostatic tissue will be enucleated along the surgical capsule plane using a thulium fibre laser system. After enucleation and haemostasis, the bladder neck will be assessed intraoperatively, and bladder neck incision will be performed according to protocol-defined anatomical and obstructive findings when considered safe by the operating surgeon.

Thulium Laser Enucleation of the Prostate: Participants will undergo transurethral thulium laser enucleation of the prostate alone. Hyperplastic prostatic tissue will be enucleated along the surgical capsule plane using a thulium fibre laser system, followed by haemostasis of the surgical wound. No bladder neck incision will be performed as part of the assigned intervention.

Transurethral Resection of the Prostate: Participants will undergo transurethral resection of the prostate using a conventional resectoscope. Obstructive hyperplastic prostatic tissue will be resected transurethrally according to standard TURP principles to relieve obstruction while avoiding excessive resection and injury to adjacent structures.

Transurethral Incision of the Prostate: Participants assigned to this intervention will undergo transurethral incision of the prostate using standard endoscopic equipment. One or two longitudinal incisions will be made at the bladder neck and prostatic urethra according to prostate morphology and the degree of obstruction. The procedure aims to relieve bladder outlet obstruction without substantial prostatic tissue resection. The incision site and extent will be individualized according to intraoperative anatomy, with careful avoidance of injury to the ureteric orifices, urethral sphincter, and adjacent structures. Haemostasis will be performed when necessary.

Study summary

This study will evaluate the safety and effectiveness of different surgical treatments for men with small-volume benign prostatic hyperplasia (BPH). Men with small-volume BPH may still have bothersome lower urinary tract symptoms and bladder outlet obstruction, and the best surgical treatment for this group remains uncertain.

In this multicentre, randomized, single-blind, four-arm controlled trial, 932 eligible men aged 40 to 80 years will be assigned in a 1:1:1:1 ratio to one of four groups: thulium laser enucleation of the prostate combined with bladder neck incision, thulium laser enucleation of the prostate alone, transurethral resection of the prostate (TURP), or transurethral incision of the prostate (TUIP).

The main goal of the study is to compare the incidence of bladder neck contracture at 6 months after surgery. Secondary outcomes include safety outcomes and changes in urinary symptoms, urinary flow rate, pain score, and symptom response at 3 and 6 months after surgery. Exploratory outcomes include changes in post-void residual urine volume and sexual function scores. Additional exploratory long-term outcomes will also be assessed at 12 months after surgery.

Eligibility

Sex
MALE
Min age
40 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Male patients aged 40-80 years. * Diagnosis of benign prostatic hyperplasia (BPH) and scheduled to undergo surgical treatment. * International Prostate Symptom Score (IPSS) of at least 12, maximum urinary flow rate of no more than 15 mL/s, with a voided volume greater than 150 mL. * Prostate volume of less than 30 mL measured by transrectal ultrasound (TRUS), calculated as length × width × height × 0.52. * Ability, as assessed by the investigator, to understand the study requirements and complete the scheduled treatment, follow-up visits, and study-related assessments. Exclusion Criteria: * Inability or refusal to provide written informed consent, or inability to comply with the required follow-up schedule. * Prostate-specific antigen (PSA) level of 10 ng/mL or higher, unless prostate cancer has been excluded by biopsy. * Confirmed or suspected prostate or bladder malignancy. * Pre-existing bladder neck contracture or urethral stricture before surgery. * Known coagulation disorder or abnormal coagulation function. * Neurogenic bladder or detrusor underactivity that may affect bladder or urethral sphincter function. * Benign prostatic hyperplasia (BPH) complicated by acute urinary tract infection, acute prostatitis, or bacterial prostatitis. * History of prostate surgery, urethral stricture, or neurogenic bladder. * History of prostate cancer or pelvic radiotherapy. * Severe cardiovascular disease, pulmonary disease, or other systemic disease that, in the investigator's judgment, would make the patient unable to tolerate surgery. * Participation in another clinical trial related to benign prostatic hyperplasia (BPH) within 3 months before enrolment. * Any other condition that, in the investigator's opinion, makes the patient unsuitable for participation in this study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Chinese PLA General Hospital Beijing Beijing Municipality

More Chinese PLA General Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07569874 on ClinicalTrials.gov ↗ ← All trials in China